Skip to main content
Yantai Zhenghai Bio-Tech Co., Ltd. logo

Yantai Zhenghai Bio-Tech Co., Ltd. — Investor Relations & Filings

Ticker · 300653 ISIN · CNE100002NZ1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 970 across all filing types
Latest filing 2022-08-18 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300653

About Yantai Zhenghai Bio-Tech Co., Ltd.

https://www.zhbio.com

Yantai Zhenghai Bio-Tech Co., Ltd. specializes in the research, development, production, and sale of regenerative medicine materials. The company focuses on tissue engineering and biomaterials to provide solutions for clinical repair and functional reconstruction. Its core product portfolio includes the Heal-All oral repair membrane, absorbable hard cerebral (spinal) membrane patches, and skin repair membranes. These products are widely utilized in stomatology, neurosurgery, and orthopedics. The company leverages advanced processing technologies to ensure biocompatibility and safety in its medical devices. By integrating research with clinical needs, it develops innovative bone repair materials and other biological scaffolds designed to facilitate natural tissue regeneration.

Recent filings

Filing Released Lang Actions
上市公司2022年半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 95% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the half-year period of 2022. It includes financial figures such as beginning balances, cumulative amounts, interest, repayments, and ending balances for related parties. The presence of specific half-year period data and detailed financial figures indicates this is a financial report for a period shorter than a full fiscal year. There is no indication that this is an announcement or a certification letter, nor is it a full annual report or an earnings release. The content fits the definition of an Interim / Quarterly Report (IR), as it contains substantive financial data and analysis for a half-year period. H1 2022
2022-08-18 Chinese
关于召开2022年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice for a shareholders' meeting, specifically the 2022 first extraordinary general meeting (临时股东大会) of Yantai Zhenghai Biotechnology Co., Ltd. It includes information about the meeting date, agenda items (such as changing the accounting firm), voting procedures (including online voting), registration details, and attachments like proxy forms and shareholder registration forms. There are no financial statements or financial performance data included. The document is primarily an announcement and procedural notice for the shareholders' meeting rather than the meeting materials or results themselves. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. Although this is an extraordinary meeting, it is still a shareholders' meeting notice, which falls under AGM Information. The document length is about 4944 characters, which is consistent with a detailed meeting notice rather than a full report or results announcement.
2022-08-18 Chinese
关于变更会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of the company's accounting firm. It details the new auditor's qualifications, reasons for the change, communication with the previous auditor, and approvals from the board, audit committee, and independent directors. It does not contain any financial statements or audit reports themselves but rather informs stakeholders about the auditor change process and approvals. The document length is 4386 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document fits the category of an Audit Report / Information announcement about auditor change, but since it is not the audit report itself, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about auditor change without the actual audit report or financial data.
2022-08-18 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is titled '监事会决议公告' which translates to 'Supervisory Board Resolution Announcement'. It details the resolutions passed by the supervisory board regarding the 2022 semi-annual report and the change of accounting firm. The document includes voting results and mentions that the full semi-annual report and related announcements are disclosed on the official regulatory website. The document length is short (1093 characters) and it does not contain the actual semi-annual financial report but rather the resolutions and approvals related to it. This fits the pattern of a formal announcement of supervisory board resolutions rather than the report itself. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about supervisory board decisions and not the actual interim report or audit report.
2022-08-18 Chinese
2022年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a '2022 年半年度报告摘要' which translates to '2022 Half-Year Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, and asset information for the half-year period. It also discusses operational highlights, product development, and company activities during the reporting period. The presence of comprehensive financial metrics and business analysis for a half-year period indicates this is an Interim / Quarterly Report. The document length is about 4862 characters, which is sufficient to contain substantive financial data and analysis, not just an announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-18 Chinese
关于医疗器械进入临床试验的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1219 characters) from a company about a medical device entering clinical trials. It includes details about the clinical trial, the product, and potential impacts on the company. There is no financial data, no mention of financial results, no regulatory certifications, or detailed report content. The document is an announcement of a clinical trial commencement, which is a regulatory or operational update rather than a financial or governance report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a voting result, board change, or capital update. Given the nature and length, it best fits under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-08-02 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.